Select your country
Select a country to go to the website of the respective STADA sales company.
Czech Republic (2)
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
Changes in the management team of STADA
- Investor News
- Press Release
- Miguel Pagan to be new Member of the Executive Board for Production and Development
- Steffen Wagner to be Head of Europe
- Carsten Cron to head Emerging Markets
- Robert Knerr to follow Wolter Kuizinga as Head of Business Development
Bad Vilbel, April 16, 2018 – STADA Arzneimittel AG (“STADA”) is systematically pushing ahead with the new strategy announced in March. Under this strategy, the Company’s focus is on the three pillars of generics, non-prescription brands and specialty pharmaceuticals such as biosimilars, together with efficiency gains in internal processes. “In order to implement this new strategic orientation as efficiently as possible, we have decided, together with the Supervisory Board, to effect a number of changes on the top management level,” said CEO Dr. Claudio Albrecht.
The previous Chief Production and Development Officer, Dr. Barthold Piening, is to be followed by Spanish-born Miguel Pagan (53) as Member of the Executive Board for Technical Operations.
The appointment of Dr. Barthold Piening as a Member of the Executive Board of STADA has been mutually cancelled with immediate effect. Dr. Piening will leave STADA end of May 2018 in order to pursue new career opportunities. STADA thanks Dr. Piening for his dedicated service and great commitment during a phase that brought many changes for STADA, as well as for the excellent collaboration, in particular during the last months. The Executive Board and Supervisory Board wish him all the best for his future endeavours.
Miguel Pagan was most recently Head of Global Technical Operations at SANDOZ and Global Head of Solids & Special Tech for overall Novartis. Before that, he was Head of all Operations of SANDOZ in Europe and India and previously Vice President of Americas Operations at Merck (MSD). “We are pleased to have gained a proven production and operations expert for STADA in Miguel Pagan. He has many years of experience in managing international production networks in large pharmaceutical groups and will further strengthen our management team,” said Dr. Günter von Au, Chairman of the Supervisory Board.
In addition, STADA has appointed three new members to its broader management team. Dr. Steffen Wagner (40) is to become Head of Europe effective July 1, 2018. He was most recently Managing Director of Biogen Germany and will take charge of all European markets except for Germany, the United Kingdom and Russia.
STADA also appointed a new Head of Emerging Markets in Carsten Cron. The 47-year-old comes from Pfizer, where he was most recently Country Manager for Morocco, Tunisia and Libya and also Commercial & Business Operations Lead for North Africa and the Middle East. To date, the Head of Europe and Head of Emerging Markets roles have both been fulfilled by CEO Albrecht.
A further change is made in the Business Development division. Wolter Kuizinga had newly established this key strategic area of the Company, making important settings of the course while heading it on an interim basis. He is to be succeeded, at the latest from September 1, by the current Vice President Portfolio Management, Dr. Robert Knerr. “This appointment underscores our approach of filling more key positions at STADA with highly qualified internal candidates going forward,” said Albrecht. As the successor to Knerr in Portfolio Management, STADA has recruited Dr. Stefan Busemann, who is joining the Company from SANDOZ.
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.
Additional information for journalists
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: email@example.com
Photo Miguel Pagan Fernandez >
CV Miguel Pagan Fernandez >
Wagner Head of Europe >
Photo Dr. Steffen Wagner >
Cron New Head of Emerging Markets >
Photo Carsten Cron >
Head of Business Devolpment >
Photo Dr. Robert Knerr >